Medical News

RSS

Walgreens offers H1N1 vaccinations at all of its pharmacies throughout Massachusetts

Walgreens, the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, is now offering H1N1 vaccinations at all of its pharmacies throughout Massachusetts.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

Spectranetics illegally imports unapproved medical devices, agrees to pay $5M for resolving allegations

Spectranetics Corporation, a medical device manufacturer, has agreed to pay the United States $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims against the company, the Justice Department announced today. The claims arise from allegations that the company illegally imported unapproved medical devices and provided them to physicians for use in patients, conducted a clinical study in a manner that failed to comply with federal regulations and promoted certain products for procedures for which the company had not received Food and Drug Administration approval or clearance.

30 Dec 2009

UC researchers receive $2.5 million grant to study treatment for voice disorders

For patients with severe voice disorders, the loss of their voice often means losing their social life, self esteem or livelihood. While existing therapies can treat mild to moderate voice disorders, physicians have a harder time determining effective treatments for those with severe cases.

30 Dec 2009

VIVUS submits a NDA to the FDA for obesity drug Qnexa

VIVUS, Inc., a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

30 Dec 2009

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.

29 Dec 2009

VIA Pharmaceuticals receives NASDAQ delisting notice

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.

29 Dec 2009

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has completed preparation to launch its flagship Xin Aoxing Oleanolic Acid ("Xin Aoxing") Capsules for the treatment of Hepatitis B in Beijing and Shanghai in early January 2010.

29 Dec 2009

Luna Innovations acquires intellectual property assets of Tego Biosciences

Luna Innovations Incorporated has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.

29 Dec 2009

Healthcare management application targeting MS patients released

A Pennsylvania-based company has just released a healthcare management application that targets Multiple Sclerosis (MS) patients to the App Store.

29 Dec 2009

H1N1 vaccine currently available at all seven Target Clinic locations in Maryland

Target® announces today that the H1N1 vaccine is currently available at all seven Target Clinic locations in Maryland, while supplies last.

29 Dec 2009

Pre-market approval by FDA of cardiovascular devices often based on studies that lack adequate strength

Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. The researchers found that of nearly 80 high-risk devices, the majority received approval based on data from a single study.

29 Dec 2009

Emerging Healthcare Solutions to execute option agreement with ThromboVision

Emerging Healthcare Solutions, Inc. is pleased to announce the execution of an exclusive option agreement with ThromboVision, Inc. ThromboVision, a Houston-based healthcare diagnostics company committed to enabling people to lead longer and healthier lives, has developed and patented T-Guide®, a new cutting-edge diagnostic test to assist medical professionals with the treatment of heart disease.

29 Dec 2009

CSL Behring awards four advocacy grants to patient organizations in the U.S.

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited, has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program.

29 Dec 2009

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

JAMA: New series on caring for the aging patient

To assist physicians in caring for a patient demographic that is rapidly growing in size, JAMA is launching a new series, "Care of the Aging Patient: From Evidence to Action."

29 Dec 2009

AspenBio Pharma reports on Premarket Notification submission plans for its ELISA format AppyScore test

AspenBio Pharma, Inc., an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, reported on its progress and plans for the Premarket Notification 510(k) submission of its ELISA format AppyScore™ test. AppyScore is the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis.

29 Dec 2009

Affomix to generate antibodies against proprietary targets chosen by Kalgene

Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.

29 Dec 2009

"America's Wellness Challenge" campaign to motivate people to change their health habits

The "Life...supplemented" consumer wellness initiative today announced America's Wellness Challenge -- three promotions spanning the next five months -- created to incentivize Americans to get serious about their health goals in 2010.

29 Dec 2009

DMET genotyping platform screens for 1256 genetic variations in 170 genes

It's the ultimate goal in the treatment of cancer: tailoring a person's therapy based on his or her genetic makeup. While a lofty goal, scientists are steadily moving forward, rapidly exploiting new technologies. Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in this field of research using a new chip that looks for hundreds of mutations in dozen of genes.

29 Dec 2009

Medical News

Walgreens offers H1N1 vaccinations at all of its pharmacies throughout Massachusetts

Phase 3 trial of figitumumab discontinued by Pfizer

Spectranetics illegally imports unapproved medical devices, agrees to pay $5M for resolving allegations

UC researchers receive $2.5 million grant to study treatment for voice disorders

VIVUS submits a NDA to the FDA for obesity drug Qnexa

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

VIA Pharmaceuticals receives NASDAQ delisting notice

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Luna Innovations acquires intellectual property assets of Tego Biosciences

Healthcare management application targeting MS patients released

H1N1 vaccine currently available at all seven Target Clinic locations in Maryland

Pre-market approval by FDA of cardiovascular devices often based on studies that lack adequate strength

Emerging Healthcare Solutions to execute option agreement with ThromboVision

CSL Behring awards four advocacy grants to patient organizations in the U.S.

Results from Bionovo's study on BN107 published

JAMA: New series on caring for the aging patient

AspenBio Pharma reports on Premarket Notification submission plans for its ELISA format AppyScore test

Affomix to generate antibodies against proprietary targets chosen by Kalgene

"America's Wellness Challenge" campaign to motivate people to change their health habits

DMET genotyping platform screens for 1256 genetic variations in 170 genes

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News